Literature DB >> 21899843

Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial.

Kiyoshi Hibi1, Takeshi Kimura, Kazuo Kimura, Takeshi Morimoto, Takafumi Hiro, Katsumi Miyauchi, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Satoshi Saito, Tetsu Yamaguchi, Hiroyuki Daida, Masunori Matsuzaki.   

Abstract

AIM: To clarify whether the effects of statin treatment on plaque regression vary according to the presence or absence of polyvascular disease (PVD) in patients with acute coronary syndrome (ACS).
METHODS: 307 patients with ACS who underwent percutaneous coronary intervention for the culprit lesion at 33 centers were treated with atorvastatin or pitavastatin. Noncoronary atherosclerosis was defined as coexistent, clinically recognized arterial disease other than coronary artery disease (CAD) (cerebral, aortic, or lower extremity). Intravascular ultrasound (IVUS) was performed to assess non-culprit coronary atherosclerosis at baseline and at 8-12 months follow-up. Serial IVUS examinations were obtained in 252 patients. Atheroma volume and percent change in atheroma volume of the target plaque was assessed.
RESULTS: Patients of the CAD+PVD (n = 19) were older (68 vs. 62 years, p = 0.02), had lower low-density lipoprotein cholesterol (LDL-C) levels at baseline (116 vs. 134 mg/dL, p=0.03) than those of the CAD-only group (n = 233), whereas LDL-C levels at follow-up were similar (81 vs. 83 mg/dL). Although the baseline plaque volume was similar in the two groups (59 vs. 57 mm(3)), patients of the CAD+PVD group showed milder regression of atherosclerosis than those of the CAD-only group (-8.9% vs. -18.2%, p = 0.005). This difference remained significant even after adjustment for coronary risk factors including age and serum LDL-C (p = 0.047).
CONCLUSIONS: Statin treatment results in milder regression of coronary atherosclerosis in CAD patients with polyvascular disease compared to those with CAD only.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21899843     DOI: 10.1016/j.atherosclerosis.2011.08.024

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

Review 1.  What We Have Learned from the Recent Meta-analyses on Diagnostic Methods for Atherosclerotic Plaque Regression.

Authors:  Giuseppe Biondi-Zoccai; Simona Mastrangeli; Enrico Romagnoli; Mariangela Peruzzi; Giacomo Frati; Leonardo Roever; Arturo Giordano
Journal:  Curr Atheroscler Rep       Date:  2018-01-17       Impact factor: 5.113

2.  Meta-Analysis of Intensive Lipid-Lowering Therapy in Patients With Polyvascular Disease.

Authors:  Mohammad Alkhalil; Michał Kuzemczak; Nicholas Whitehead; Charalampos Kavvouras; Vladimír Džavík
Journal:  J Am Heart Assoc       Date:  2021-02-15       Impact factor: 5.501

3.  Impact of Enhanced Production of Endogenous Heme Oxygenase-1 by Pitavastatin on Survival and Functional Activities of Bone Marrow-derived Mesenchymal Stem Cells.

Authors:  Masa-Aki Kawashiri; Chiaki Nakanishi; Toshinari Tsubokawa; Masaya Shimojima; Shohei Yoshida; Tsuyoshi Yoshimuta; Tetsuo Konno; Masakazu Yamagishi; Kenshi Hayashi
Journal:  J Cardiovasc Pharmacol       Date:  2015-06       Impact factor: 3.105

4.  Rosuvastatin-attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway.

Authors:  Zhaohui Qiu; Wenbin Zhang; Fan Fan; Hua Li; Chaoneng Wu; Yong Ye; Qijun Du; Zheng Li; Xiaona Hu; Gang Zhao; Aijun Sun; Zhijun Bao; Junbo Ge
Journal:  J Cell Mol Med       Date:  2012-12       Impact factor: 5.310

5.  Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease.

Authors:  Rutao Wang; Scot Garg; Chao Gao; Hideyuki Kawashima; Masafumi Ono; Hironori Hara; Robert-Jan van Geuns; Marie-Claude Morice; Piroze M Davierwala; Arie Pieter Kappetein; David R Holmes; William Wijns; Ling Tao; Yoshinobu Onuma; Patrick W Serruys
Journal:  Clin Res Cardiol       Date:  2021-08-25       Impact factor: 5.460

Review 6.  The prevention and regression of atherosclerotic plaques: emerging treatments.

Authors:  Atul Ashok Kalanuria; Paul Nyquist; Geoffrey Ling
Journal:  Vasc Health Risk Manag       Date:  2012-09-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.